Top-Rated StocksTop-RatedNASDAQ:BBIO BridgeBio Pharma (BBIO) Stock Price, News & Analysis $27.05 +0.35 (+1.31%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$26.61▼$27.8250-Day Range$23.00▼$29.5252-Week Range$21.62▼$44.32Volume885,913 shsAverage Volume1.83 million shsMarket Capitalization$5.06 billionP/E RatioN/ADividend YieldN/APrice Target$48.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get BridgeBio Pharma alerts: Email Address BridgeBio Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside80.1% Upside$48.73 Price TargetShort InterestBearish14.95% of Float Sold ShortDividend StrengthN/ASustainability-2.31Upright™ Environmental ScoreNews Sentiment0.32Based on 8 Articles This WeekInsider TradingSelling Shares$28,840 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.20) to ($2.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.42 out of 5 starsMedical Sector132nd out of 936 stocksPharmaceutical Preparations Industry52nd out of 436 stocks 4.5 Analyst's Opinion Consensus RatingBridgeBio Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBridgeBio Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Pharma's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.95% of the float of BridgeBio Pharma has been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in BridgeBio Pharma has recently increased by 5.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBridgeBio Pharma does not currently pay a dividend.Dividend GrowthBridgeBio Pharma does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBridgeBio Pharma has received a 53.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Infigratinib", "Fosdenopterin", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for BridgeBio Pharma is -2.31. Previous Next 1.8 News and Social Media Coverage News SentimentBridgeBio Pharma has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for BridgeBio Pharma this week, compared to 5 articles on an average week.Search InterestOnly 9 people have searched for BBIO on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,840.00 in company stock.Percentage Held by Insiders24.66% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BridgeBio Pharma are expected to grow in the coming year, from ($3.20) to ($2.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Pharma is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Pharma is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BridgeBio Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...Click here to see how >>> About BridgeBio Pharma Stock (NASDAQ:BBIO)BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Read More BBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BBIO Stock News HeadlinesJuly 26 at 12:27 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJuly 24 at 8:57 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 23 at 7:30 AM | globenewswire.comBridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating OfficerJuly 20, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJuly 20, 2024 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Trading Down 2.9%July 18, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJuly 18, 2024 | americanbankingnews.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $47.21 Average PT from BrokeragesJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 12, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJuly 10, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJuly 10, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJuly 7, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJuly 7, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJuly 5, 2024 | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJune 30, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJune 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOSee More Headlines Receive BBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BBIO CUSIPN/A CIK1743881 Webbridgebio.com Phone(650) 391-9740FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Stock Price Target$48.73 High Stock Price Target$70.00 Low Stock Price Target$37.00 Potential Upside/Downside+79.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-643,200,000.00 Net Margins-246.24% Pretax Margin-250.09% Return on EquityN/A Return on Assets-80.12% Debt Debt-to-Equity RatioN/A Current Ratio5.54 Quick Ratio5.54 Sales & Book Value Annual Sales$9.30 million Price / Sales545.90 Cash FlowN/A Price / Cash FlowN/A Book Value($7.72) per share Price / Book-3.51Miscellaneous Outstanding Shares187,130,000Free Float140,983,000Market Cap$5.08 billion OptionableOptionable Beta1.06 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Neil Kumar Ph.D. (Age 45)Co-Founder, President, CEO & Director Comp: $1.53MDr. Charles J. Homcy M.D. (Age 76)Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director Comp: $563.2kDr. Frank P. McCormick Ph.D. (Age 74)Co-Founder, Chairman of Oncology & Director Comp: $542.78kDr. Brian C. Stephenson C.F.A. (Age 43)Ph.D., CFO & Secretary Comp: $1.15MDr. Richard H. Scheller Ph.D. (Age 71)Chairman of Research & Development Comp: $509.62kDr. Uma Sinha Ph.D. (Age 66)Chief Scientific Officer Comp: $1.31MGrace RauhVice President of CommunicationsMr. Eli M. Wallace Ph.D. (Age 57)Chief Scientific Officer of Oncology Dr. Thomas Trimarchi Ph.D.Chief Product OfficerDr. Eric Michael David J.D. (Age 52)M.D., Ph.D., Chief Executive Officer of Gene Therapy More ExecutivesKey CompetitorsTurning Point TherapeuticsNASDAQ:TPTXReata PharmaceuticalsNASDAQ:RETAAmicus TherapeuticsNASDAQ:FOLDSchrödingerNASDAQ:SDGRAllakosNASDAQ:ALLKView All CompetitorsInsiders & InstitutionsHennion & Walsh Asset Management Inc.Sold 104,995 shares on 7/20/2024Ownership: 0.021%Nisa Investment Advisors LLCSold 7,069 shares on 7/20/2024Ownership: 0.017%China Universal Asset Management Co. Ltd.Sold 11,790 shares on 7/20/2024Ownership: 0.012%Portman Square Capital LLPSold 457,400 shares on 7/19/2024Ownership: 0.000%Assenagon Asset Management S.A.Bought 239,900 shares on 7/18/2024Ownership: 0.132%View All Insider TransactionsView All Institutional Transactions BBIO Stock Analysis - Frequently Asked Questions How have BBIO shares performed this year? BridgeBio Pharma's stock was trading at $40.37 at the beginning of the year. Since then, BBIO stock has decreased by 33.0% and is now trading at $27.05. View the best growth stocks for 2024 here. How were BridgeBio Pharma's earnings last quarter? BridgeBio Pharma, Inc. (NASDAQ:BBIO) issued its quarterly earnings data on Thursday, May, 2nd. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.35. The business had revenue of $211.12 million for the quarter, compared to analysts' expectations of $140.06 million. When did BridgeBio Pharma IPO? BridgeBio Pharma (BBIO) raised $225 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 15,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers. Who are BridgeBio Pharma's major shareholders? Top institutional investors of BridgeBio Pharma include Assenagon Asset Management S.A. (0.13%), Portman Square Capital LLP, Hennion & Walsh Asset Management Inc. (0.02%) and Diversified Trust Co (0.02%). Insiders that own company stock include Global Investors Lp Viking, Neil Kumar, Frank Mccormick, Brian C Stephenson, Randal W Scott, Hannah Valantine, Ronald J Daniels, Douglas A Dachille and Richard H Scheller. View institutional ownership trends. How do I buy shares of BridgeBio Pharma? Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BridgeBio Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU) and Editas Medicine (EDIT). This page (NASDAQ:BBIO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BBIO Stock Alerts